• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.07% Nasdaq Up0.12%

    Exelixis, Inc. (EXEL)

    5.50 0.00(0.00%) 9:33AM EST - Nasdaq Real Time Price
    ProfileGet Profile for:
    Exelixis, Inc.
    210 East Grand Avenue
    South San Francisco, CA 94080
    United States - Map
    Phone: 650-837-7000
    Fax: 650-837-8300
    Website: http://www.exelixis.com

    Index Membership:N/A
    Full Time Employees:98

    Business Summary 

    Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer. It is also evaluating cabozantinib in various development programs comprising approximately 45 clinical trials, including 2 ongoing phase 3 pivotal trials focusing on metastatic renal cell carcinoma (mRCC) and advanced hepatocellular carcinoma (HCC). In addition, the company develops cobimetinib, an inhibitor of MEK, which is in Phase 3 pivotal trial evaluating in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation. Exelixis, Inc. has collaborations with Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Exelixis, Inc.

    Corporate Governance 
    Exelixis, Inc.’s ISS Governance QuickScore as of Nov 1, 2015 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 5; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Stelios Papadopoulos Ph.D., 67
    Chairman and Member of Audit Committee
    Dr. Michael M. Morrissey Ph.D., 54
    Chief Exec. Officer, Pres and Director
    Mr. Peter Lamb Ph.D., 54
    Chief Scientific Officer and Exec. VP of Discovery Research
    Mr. Jeffrey J. Hessekiel J.D., 46
    Exec. VP, Gen. Counsel and Sec.
    Dr. Gisela M. Schwab M.D., 58
    Exec. VP and Chief Medical Officer
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders